These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38465961)

  • 1. Extravasation After [ 177 Lu]Lu-HA-DOTATATE Therapy.
    de Vries-Huizing DMV; Cheung ZJ; Hendrikx JJMA; Donswijk ML; Versleijen MWJ
    Clin Nucl Med; 2024 May; 49(5):454-456. PubMed ID: 38465961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striking Size Reduction of Rapidly Growing Pancreatic Neuroendocrine Carcinoma Metastatic Nodal Conglomerate After Only 2 Cycles of 177 Lu-DOTATATE.
    Somoza EA; Duan H; Shaheen S; Fischer GA; Aparici CM
    Clin Nucl Med; 2022 Nov; 47(11):961-962. PubMed ID: 35695695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [
    Vigne J; Chrétien B; Bignon AL; Bouhier-Leporrier K; Dolladille C
    Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3332-3333. PubMed ID: 35513605
    [No Abstract]   [Full Text] [Related]  

  • 4. An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium 177 (
    Kovan B; Özkan ZG; Demir B; Tunçman D; Işik EG; Şimşek DH; Büyükkaya F; Türkmen C; Şanli Y
    Cancer Biother Radiopharm; 2022 Feb; 37(1):17-22. PubMed ID: 34134512
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of a Patient With Metastatic Gastrointestinal Neuroendocrine Tumor and Meningioma Submitted to Peptide Receptor Radionuclide Therapy With 177 Lu-DOTATATE.
    Pirisino R; Filippi L; D'Agostini A; Bagni O
    Clin Nucl Med; 2022 Nov; 47(11):e692-e695. PubMed ID: 35695716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amino acid extravasation: a rare red flag to keep in mind during peptide receptor radioligand therapy (PRRT) with [177Lu]Lu-DOTATATE.
    Divband G; Alavi SH; Adinehpour Z; Kalantari F; Zarehparvar Moghadam S
    Nucl Med Rev Cent East Eur; 2022; 25(2):136-137. PubMed ID: 35848524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea.
    Shin Y; Moon BH; Ryoo BY; Chang HM; Kim KP; Hong YS; Kim TW; Ryu JS; Kim YI; Yoo C
    Target Oncol; 2024 Jan; 19(1):41-49. PubMed ID: 38108953
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Abbott A; Jacene H
    J Nucl Med Technol; 2022 Sep; 50(3):203-204. PubMed ID: 36215643
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm.
    Bober B; Saracyn M; Lubas A; Kolodziej M; Brodowska-Kania D; Kapusta W; Kaminski G
    Nucl Med Rev Cent East Eur; 2022; 25(1):54-61. PubMed ID: 35137938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Hervás I; Bello P; Falgas M; Del Olmo MI; Torres I; Olivas C; Vera V; Oliván P; Yepes AM
    Rev Esp Med Nucl Imagen Mol; 2017; 36(2):91-98. PubMed ID: 27889527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.
    Bergsma H; Konijnenberg MW; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Franssen GJ; van Eijck CH; Krenning EP; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):453-63. PubMed ID: 26419852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 177 Lu-DOTATATE PRRT for Multiple Unusual Metastatic Sites in Neuroendocrine Tumor.
    Parghane RV; Basu S
    Clin Nucl Med; 2022 Oct; 47(10):874-875. PubMed ID: 35353741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
    Love C; Desai NB; Abraham T; Banks KP; Bodei L; Boike T; Brown RKJ; Bushnell DL; DeBlanche LE; Dominello MM; Francis T; Grady EC; Hobbs RF; Hope TA; Kempf JS; Pryma DA; Rule W; Savir-Baruch B; Sethi I; Subramaniam RM; Xiao Y; Schechter NR
    Clin Nucl Med; 2022 Jun; 47(6):503-511. PubMed ID: 35507433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High clinical and morphologic response using
    Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with
    Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L
    Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study.
    Wild D; Fani M; Fischer R; Del Pozzo L; Kaul F; Krebs S; Fischer R; Rivier JE; Reubi JC; Maecke HR; Weber WA
    J Nucl Med; 2014 Aug; 55(8):1248-52. PubMed ID: 24963127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
    Kulkarni HR; Schuchardt C; Baum RP
    Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET.
    Ianniello A; Sansovini M; Severi S; Nicolini S; Grana CM; Massri K; Bongiovanni A; Antonuzzo L; Di Iorio V; Sarnelli A; Caroli P; Monti M; Scarpi E; Paganelli G
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1040-6. PubMed ID: 26611427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.